Home/StemSight/Laura Koivusalo

LK

Laura Koivusalo

CEO

Therapeutic Areas

Ophthalmology Corneal Blindness

StemSight Pipeline

Drug	Indication	Phase
iPSC-derived Limbal Stem Cell Therapy	Limbal Stem Cell Deficiency (LSCD) leading to corneal blindness	Pre-clinical

Leadership Team at StemSight

Tanja Ilmarinen

Chief Scientific Officer (CSO)

Chief Commercial Officer (CCO)

Founding Scientist / Professor

View full StemSight profile